Heron Therapeutics (HRTX) Tops Q3 EPS by 12c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.17), $0.12 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $31.43 million versus the consensus estimate of $32.75 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)
• Morgan Stanley Upgrades Coal India Ltd (COAL:IN) to Overweight